205 related articles for article (PubMed ID: 22784880)
1. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
2. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
[No Abstract] [Full Text] [Related]
3. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
7. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Hopkins AM; O'Doherty CE; Foster DJ; Suppiah V; Upton RN; Spargo LD; Cleland LG; Proudman SM; Wiese MD
J Clin Pharm Ther; 2014 Oct; 39(5):555-60. PubMed ID: 25040563
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
Russo PA; Wiese MD; Smith MD; Ahern MJ; Barbara JA; Shanahan EM
Ann Pharmacother; 2013 Mar; 47(3):e15. PubMed ID: 23447478
[TBL] [Abstract][Full Text] [Related]
9. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
10. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
11. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
O'Doherty C; Schnabl M; Spargo L; Cleland LG; James M; Proudman SM; Wiese MD
Pharmacogenomics; 2012 Sep; 13(12):1427-34. PubMed ID: 22966891
[TBL] [Abstract][Full Text] [Related]
12. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
13. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
Machaj F; Rosik J; Szostak B; Malinowski D; Safranow K; Olędzka G; Wiechec E; Pawlik A
Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
Alivernini S; Mazzotta D; Zoli A; Ferraccioli G
Drugs Aging; 2009; 26(5):395-402. PubMed ID: 19552491
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
16. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
17. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Van Roon EN; Jansen TL; Mourad L; Houtman PM; Bruyn GA; Griep EN; Wilffert B; Tobi H; Brouwers JR
Br J Clin Pharmacol; 2004 Aug; 58(2):201-8. PubMed ID: 15255803
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.
Ren LM; Li R; Chen LN; Zhu P; Gu F; Sun LY; Zhao JX; Liu XY; Guo JL; Bi LQ; Hao YJ; Zhang ZL; Mei YF; Zhang ZY; Liu HX; Li XF; Luo Y; Fang YF; Li ZG; Su Y
Int J Rheum Dis; 2016 Jul; 19(7):651-7. PubMed ID: 26268935
[TBL] [Abstract][Full Text] [Related]
20. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
[Next] [New Search]